When Baxter told Spectral not to share crude interim data with the market- as described on the latest call by Seto and Kellum. (~ min 21)
- was Spectral aware that Baxter was in discussions re: selling off Vantive to Private Equity firm?
Was Spectral aware of Baxter’s discussions when Spectral agreed to Baxter’s amended distribution agreement? Assigning rights to:
The separated “Kidney Care business (or any other separation of all or part of such Kidney Care business) into an independent company”
Clearly management is “all in” on Baxter/ Vantive being our buyer… but do they know anything about the plans or interest of Vantive’s buyer?
Withholding crude data not only clearly hurt Spectral’s SP, but it keeps PMX and it’s “exceeding expectations” trial from the view of other would be buyers.
Spectral should be acting on what’s best for Spectral- not what is best for “possible” buyer Vantive- or for Vantive's possible buyer…